Stratos Wealth Partners’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Stratos Wealth Partners’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$257K	Sell	7,484 -150	-2%	-$5.13K	﹤0.01%	1408
2025 Q4	$251K	Sell	7,634 -428	-5%	-$13.3K	﹤0.01%	1388
2025 Q3	$230K	Buy	+8,062	New	+$219K	﹤0.01%	1390
2024 Q3	–	Sell	-8,361	Closed	-$228K	–	1475
2024 Q2	$228K	Sell	8,361 -822	-9%	-$22K	﹤0.01%	1216
2024 Q1	$257K	Buy	+9,183	New	+$253K	﹤0.01%	1165
2018 Q4	–	Sell	-501	Closed	-$12K	–	1441
2018 Q3	$12K	Buy	+501	New	+$11.6K	﹤0.01%	2088

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $208M AUM 30.96% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.28B AUM 27.63% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Stratos Wealth Partners's FTXH Position: Q1 2026 in Review

Stratos Wealth Partners reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 2% in Q1 2026, selling an estimated $5.13K and leaving 7,484 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Stratos Wealth Partners first reported a position in FTXH in Q3 2018 and has held it in 6 quarters since. The position peaked at $257K in Q1 2024. 32 funds tracked by Wall St. Rank hold FTXH as of Q1 2026.

Stratos Wealth Partners held 7,484 shares of First Trust Nasdaq Pharmaceuticals ETF worth $257K as of Q1 2026.
Stratos Wealth Partners sold 150 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2026, an estimated $5.13K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #1408 holding.
Stratos Wealth Partners first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2018 and has held it in 6 quarters since.
Stratos Wealth Partners's First Trust Nasdaq Pharmaceuticals ETF position peaked at $257K in Q1 2024.
32 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.